Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-240 pembrolizumab versus placebo with best supportive care in previously treated advanced hepatocellular carcinoma
MOH_2017-03-22_000187Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2017-03-22_000187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-22_000187.